Yifan Xinfu Pharmaceutical Co Ltd (002019) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Yifan Xinfu Pharmaceutical Co Ltd (002019) has a cash flow conversion efficiency ratio of 0.005x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥40.18 Million ≈ $5.88 Million USD) by net assets (CN¥8.71 Billion ≈ $1.27 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 002019 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Yifan Xinfu Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2003–2025)
This chart illustrates how Yifan Xinfu Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Yifan Xinfu Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Yifan Xinfu Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Grupo Mateus S.A
SA:GMAT3
|
0.056x |
|
Polaris Bay Group Co Ltd
SHG:600155
|
0.087x |
|
Shanghai Jahwa United Co Ltd
SHG:600315
|
0.020x |
|
Zymeworks Inc. Common Stock
NASDAQ:ZYME
|
-0.098x |
|
Hunan Oil Pump
SHG:603319
|
0.018x |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
0.048x |
|
Kraken Robotics Inc
V:PNG
|
-0.046x |
|
Guangdong Hoshion Aluminium Co Ltd
SHE:002824
|
0.069x |
Annual Cash Flow Conversion Efficiency for Yifan Xinfu Pharmaceutical Co Ltd (2003–2025)
The table below shows the annual cash flow conversion efficiency of Yifan Xinfu Pharmaceutical Co Ltd from 2003 to 2025. For the full company profile with market capitalisation and key ratios, see 002019 market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥8.71 Billion ≈ $1.27 Billion |
CN¥458.37 Million ≈ $67.07 Million |
0.053x | -30.80% |
| 2024-12-31 | CN¥8.43 Billion ≈ $1.23 Billion |
CN¥640.73 Million ≈ $93.76 Million |
0.076x | +80.06% |
| 2023-12-31 | CN¥8.25 Billion ≈ $1.21 Billion |
CN¥348.58 Million ≈ $51.01 Million |
0.042x | -18.18% |
| 2022-12-31 | CN¥9.15 Billion ≈ $1.34 Billion |
CN¥472.07 Million ≈ $69.08 Million |
0.052x | +50.34% |
| 2021-12-31 | CN¥8.78 Billion ≈ $1.28 Billion |
CN¥301.23 Million ≈ $44.08 Million |
0.034x | -73.01% |
| 2020-12-31 | CN¥8.72 Billion ≈ $1.28 Billion |
CN¥1.11 Billion ≈ $162.21 Million |
0.127x | +6.13% |
| 2019-12-31 | CN¥7.82 Billion ≈ $1.14 Billion |
CN¥937.24 Million ≈ $137.15 Million |
0.120x | -29.51% |
| 2018-12-31 | CN¥6.89 Billion ≈ $1.01 Billion |
CN¥1.17 Billion ≈ $171.34 Million |
0.170x | +1.79% |
| 2017-12-31 | CN¥6.78 Billion ≈ $992.46 Million |
CN¥1.13 Billion ≈ $165.75 Million |
0.167x | -23.88% |
| 2016-12-31 | CN¥3.90 Billion ≈ $570.77 Million |
CN¥855.85 Million ≈ $125.24 Million |
0.219x | +57.24% |
| 2015-12-31 | CN¥2.88 Billion ≈ $421.52 Million |
CN¥401.96 Million ≈ $58.82 Million |
0.140x | +154.00% |
| 2014-12-31 | CN¥2.54 Billion ≈ $372.19 Million |
CN¥139.74 Million ≈ $20.45 Million |
0.055x | -38.38% |
| 2013-12-31 | CN¥384.95 Million ≈ $56.33 Million |
CN¥34.32 Million ≈ $5.02 Million |
0.089x | +43.45% |
| 2012-12-31 | CN¥480.81 Million ≈ $70.36 Million |
CN¥29.88 Million ≈ $4.37 Million |
0.062x | +155.24% |
| 2011-12-31 | CN¥469.52 Million ≈ $68.71 Million |
CN¥-52.82 Million ≈ $-7.73 Million |
-0.113x | -134.03% |
| 2010-12-31 | CN¥703.64 Million ≈ $102.96 Million |
CN¥-33.82 Million ≈ $-4.95 Million |
-0.048x | -174.89% |
| 2009-12-31 | CN¥913.15 Million ≈ $133.62 Million |
CN¥58.61 Million ≈ $8.58 Million |
0.064x | -56.02% |
| 2008-12-31 | CN¥570.87 Million ≈ $83.54 Million |
CN¥83.31 Million ≈ $12.19 Million |
0.146x | -67.81% |
| 2007-12-31 | CN¥548.55 Million ≈ $80.27 Million |
CN¥248.71 Million ≈ $36.39 Million |
0.453x | +351.02% |
| 2006-12-31 | CN¥324.46 Million ≈ $47.48 Million |
CN¥32.62 Million ≈ $4.77 Million |
0.101x | +33.73% |
| 2005-12-31 | CN¥320.93 Million ≈ $46.96 Million |
CN¥24.12 Million ≈ $3.53 Million |
0.075x | -30.63% |
| 2004-12-31 | CN¥309.98 Million ≈ $45.36 Million |
CN¥33.59 Million ≈ $4.91 Million |
0.108x | -19.25% |
| 2003-12-31 | CN¥94.31 Million ≈ $13.80 Million |
CN¥12.65 Million ≈ $1.85 Million |
0.134x | -- |
About Yifan Xinfu Pharmaceutical Co Ltd
Yifan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products, vitamins, and polymer materials in China, South Korea, the Philippines, Vietnam, Italy, Thailand, and internationally. It offers pharmaceutical products, such as biopharmaceuticals, chemical drugs, and traditional Chinese medicines; vitamin products, including vitamin B5 and provi… Read more